fractory Anaplastic Astrocytoma
For adults the initial dose is 150 mg/m 2 orally once daily for 5 consecutive days per 28-day treatment cycle. For adult patients, if both the nadir and day of dosing (Day 29, Day 1 of next cycle) ANC are >/=1.5 × 10 9 /L (1500/µL) and both the nadir and Day 29, Day 1 of next cycle platelet counts are >/=100 × 10 9 /L (100,000/µL), the TEMODAR dose may be increased to 200 mg/m 2 /day for 5 consecutive days per 28-day treatment cycle. During treatment, a complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5 × 10 9 /L (1500/µL) and the platelet count exceeds 100 × 10 9 /L (100,000/µL). The next cycle of TEMODAR should not be started until the ANC and platelet count exceed these levels. If the ANC falls to <1.0 × 10 9 /L (1000/µL) or the platelet count is <50 × 10 9 /L (50,000/µL) during any cycle, the next cycle should be reduced by 50 mg/m 2 , but not below 100 mg/m 2 , the lowest recommended dose (see Table 8 ). TEMODAR therapy can be continued until disease progression. In the clinical trial, treatment could be continued for a maximum of 2 years; but the optimum duration of therapy is not known.
Table 9
Daily Dose Calculations by Body Surface Area (BSA)
Total BSA
(m 2 ) 75 mg/m 2
(mg daily) 150 mg/m 2
(mg daily) 200 mg/m 2
(mg daily)
1.0 75 150 200
1.1 82.5 165 220
1.2 90 180 240
1.3 97.5 195 260
1.4 105 210 280
1.5 112.5 225 300
1.6 120 240 320
1.7 127.5 255 340
1.8 135 270 360
1.9 142.5 285 380
2.0 150 300 400
2.1 157.5 315 420
2.2 165 330 440
2.3 172.5 345 460
2.4 180 360 480
2.5 187.5 375 500
Table 10 Suggested Capsule Combinations Based on Daily Dose
in Adults
Number of Daily Capsules by Strength (mg)
Total Daily Dose (mg) 250 100 20 5
75 0&nb |
